MAY 2017 Deal Watch Review AVAILABLE NOW.
Campbell worked in the pharmaceutical industry for almost 35 years, the last 25 of which were at AstraZeneca where he held several senior business development positions. Campbell has experience of all aspects of business development but his main focus has been on transactions. He has successfully negotiated over 50 deals. As former Executive Director of Science & Technology Licensing at AstraZeneca, Campbell’s primary expertise is in early stage R&D transactions. In addition, he has significant experience of Oncology therapy area deals where he in-licensed products such as selumetinib from Array Biopharma and volitinib from Hutchison Medipharma.
Campbell’s background is in science. He has a BSc in pharmacology from Edinburgh University and a PhD in cardiovascular pharmacology from the University of Wales. He was formerly with Beecham Pharmaceuticals (now GSK) before joining ICI Pharmaceuticals (now AstraZeneca) in 1989 as Head of General Pharmacology. He was also R&D Project Leader of the team that discovered zibotentan which was in Phase III clinical development for prostate cancer. Campbell took up his first business development role in 1996.
Campbell is also Chairman of the UK Pharmaceutical Licensing Group (PLG).